Skip to main content
NCBI home page
Archives of Disease in Childhood. Fetal and Neonatal Edition logoLink to Archives of Disease in Childhood. Fetal and Neonatal Edition
. 2000 Nov;83(3):F177–F181. doi: 10.1136/fn.83.3.F177

Early postnatal dexamethasone treatment and increased incidence of cerebral palsy

E Shinwell, M Karplus, D Reich, Z Weintraub, S Blazer, D Bader, S Yurman, T Dolfin, A Kogan, S Dollberg, E Arbel, M Goldberg, I Gur, N Naor, L Sirota, S Mogilner, A Zaritsky, M Barak, E Gottfried
PMCID: PMC1721173  PMID: 11040164

Abstract

OBJECTIVE—To study the long term neurodevelopmental outcome of children who participated in a randomised, double blind, placebo controlled study of early postnatal dexamethasone treatment for prevention of chronic lung disease.
METHODS—The original study compared a three day course of dexamethasone (n = 132) with a saline placebo (n = 116) administered from before 12 hours of age in preterm infants, who were ventilated for respiratory distress syndrome and had received surfactant treatment. Dexamethasone treatment was associated with an increased incidence of hypertension, hyperglycaemia, and gastrointestinal haemorrhage and no reduction in either the incidence or severity of chronic lung disease or mortality. A total of 195 infants survived to discharge and five died later. Follow up data were obtained on 159 of 190 survivors at a mean (SD) age of 53 (18) months.
RESULTS—No differences were found between the groups in terms of perinatal or neonatal course, antenatal steroid administration, severity of initial disease, or major neonatal morbidity. Dexamethasone treated children had a significantly higher incidence of cerebral palsy than those receiving placebo (39/80 (49%) v 12/79 (15%) respectively; odds ratio (OR) 4.62, 95% confidence interval (95% CI) 2.38 to 8.98). The most common form of cerebral palsy was spastic diplegia (incidence 22/80 (28%) v 5/79 (6%) in dexamethasone and placebo treated infants respectively; OR 4.45, 95% CI 1.95to 10.15). Developmental delay was significantly more common in the dexamethasone treated group (44/80 (55%)) than in the placebo treated group (23/79 (29%); OR 2.87, 95% CI 1.53 to 5.38). Dexamethasone treated infants had more periventricular leucomalacia and less intraventricular haemorrhage in the neonatal period than those in the placebo group, although these differences were not statistically significant. Eleven children with cerebral palsy had normal ultrasound scans in the neonatal period; all 11 had received dexamethasone. Logistic regression analysis showed both periventricular leucomalacia and drug assignment to dexamethasone to be highly significant predictors of abnormal neurological outcome.
CONCLUSIONS—A three day course of dexamethasone administered shortly after birth in preterm infants with respiratory distress syndrome is associated with a significantly increased incidence of cerebral palsy and developmental delay.



Full Text

The Full Text of this article is available as a PDF (128.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baden M., Bauer C. R., Colle E., Klein G., Taeusch H. W., Jr, Stern L. A controlled trial of hydrocortisone therapy in infants with respiratory distress syndrome. Pediatrics. 1972 Oct;50(4):526–534. [PubMed] [Google Scholar]
  2. Baud O., Foix-L'Helias L., Kaminski M., Audibert F., Jarreau P. H., Papiernik E., Huon C., Lepercq J., Dehan M., Lacaze-Masmonteil T. Antenatal glucocorticoid treatment and cystic periventricular leukomalacia in very premature infants. N Engl J Med. 1999 Oct 14;341(16):1190–1196. doi: 10.1056/NEJM199910143411604. [DOI] [PubMed] [Google Scholar]
  3. Benesová O., Pavlík A. Perinatal treatment with glucocorticoids and the risk of maldevelopment of the brain. Neuropharmacology. 1989 Jan;28(1):89–97. doi: 10.1016/0028-3908(89)90073-7. [DOI] [PubMed] [Google Scholar]
  4. Cummings J. J., D'Eugenio D. B., Gross S. J. A controlled trial of dexamethasone in preterm infants at high risk for bronchopulmonary dysplasia. N Engl J Med. 1989 Jun 8;320(23):1505–1510. doi: 10.1056/NEJM198906083202301. [DOI] [PubMed] [Google Scholar]
  5. Giedion A., Haefliger H., Dangel P. Acute pulmonary X-ray changes in hyaline membrane disease treated with artificial ventilation and positive end-expiratory pressure (PEP). Pediatr Radiol. 1973 Oct;1(3):145–152. doi: 10.1007/BF00974058. [DOI] [PubMed] [Google Scholar]
  6. Halliday H. L. Clinical trials of postnatal corticosteroids: inhaled and systemic. Biol Neonate. 1999 Jun;76 (Suppl 1):29–40. doi: 10.1159/000047044. [DOI] [PubMed] [Google Scholar]
  7. Jones R., Wincott E., Elbourne D., Grant A. Controlled trial of dexamethasone in neonatal chronic lung disease: a 3-year follow-up. Pediatrics. 1995 Nov;96(5 Pt 1):897–906. [PubMed] [Google Scholar]
  8. Noble-Jamieson C. M., Regev R., Silverman M. Dexamethasone in neonatal chronic lung disease: pulmonary effects and intracranial complications. Eur J Pediatr. 1989 Jan;148(4):365–367. doi: 10.1007/BF00444135. [DOI] [PubMed] [Google Scholar]
  9. O'Shea T. M., Kothadia J. M., Klinepeter K. L., Goldstein D. J., Jackson B. G., Weaver R. G., 3rd, Dillard R. G. Randomized placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants: outcome of study participants at 1-year adjusted age. Pediatrics. 1999 Jul;104(1 Pt 1):15–21. doi: 10.1542/peds.104.1.15. [DOI] [PubMed] [Google Scholar]
  10. Papile L. A., Tyson J. E., Stoll B. J., Wright L. L., Donovan E. F., Bauer C. R., Krause-Steinrauf H., Verter J., Korones S. B., Lemons J. A. A multicenter trial of two dexamethasone regimens in ventilator-dependent premature infants. N Engl J Med. 1998 Apr 16;338(16):1112–1118. doi: 10.1056/NEJM199804163381604. [DOI] [PubMed] [Google Scholar]
  11. Rastogi A., Akintorin S. M., Bez M. L., Morales P., Pildes R. S. A controlled trial of dexamethasone to prevent bronchopulmonary dysplasia in surfactant-treated infants. Pediatrics. 1996 Aug;98(2 Pt 1):204–210. [PubMed] [Google Scholar]
  12. Reist M., Marshall K. A., Jenner P., Halliwell B. Toxic effects of sulphite in combination with peroxynitrite on neuronal cells. J Neurochem. 1998 Dec;71(6):2431–2438. doi: 10.1046/j.1471-4159.1998.71062431.x. [DOI] [PubMed] [Google Scholar]
  13. Sanders R. J., Cox C., Phelps D. L., Sinkin R. A. Two doses of early intravenous dexamethasone for the prevention of bronchopulmonary dysplasia in babies with respiratory distress syndrome. Pediatr Res. 1994 Jul;36(1 Pt 1):122–128. doi: 10.1203/00006450-199407001-00022. [DOI] [PubMed] [Google Scholar]
  14. Shinwell E. S., Karplus M., Zmora E., Reich D., Rothschild A., Blazer S., Bader D., Yurman S., Dolfin T., Kuint J. Failure of early postnatal dexamethasone to prevent chronic lung disease in infants with respiratory distress syndrome. Arch Dis Child Fetal Neonatal Ed. 1996 Jan;74(1):F33–F37. doi: 10.1136/fn.74.1.f33. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Suske G., Oestreich K., Varnholt V., Lasch P., Kachel W. Influence of early postnatal dexamethasone therapy on ventilator dependency in surfactant-substituted preterm infants. Acta Paediatr. 1996 Jun;85(6):713–718. doi: 10.1111/j.1651-2227.1996.tb14132.x. [DOI] [PubMed] [Google Scholar]
  16. Tapia J. L., Ramírez R., Cifuentes J., Fabres J., Hübner M. E., Bancalari A., Mercado M. E., Standen J., Escobar M. The effect of early dexamethasone administration on bronchopulmonary dysplasia in preterm infants with respiratory distress syndrome. J Pediatr. 1998 Jan;132(1):48–52. doi: 10.1016/s0022-3476(98)70483-4. [DOI] [PubMed] [Google Scholar]
  17. Tsubota S., Adachi N., Chen J., Yorozuya T., Nagaro T., Arai T. Dexamethasone changes brain monoamine metabolism and aggravates ischemic neuronal damage in rats. Anesthesiology. 1999 Feb;90(2):515–523. doi: 10.1097/00000542-199902000-00028. [DOI] [PubMed] [Google Scholar]
  18. Tuor U. I., Simone C. S., Barks J. D., Post M. Dexamethasone prevents cerebral infarction without affecting cerebral blood flow in neonatal rats. Stroke. 1993 Mar;24(3):452–457. doi: 10.1161/01.str.24.3.452. [DOI] [PubMed] [Google Scholar]
  19. Vicedomini J. P., Nonneman A. J., DeKosky S. T., Scheff S. W. Perinatal glucocorticoids disrupt learning: a sexually dimorphic response. Physiol Behav. 1986 Jan;36(1):145–149. doi: 10.1016/0031-9384(86)90088-0. [DOI] [PubMed] [Google Scholar]
  20. Yeh T. F., Torre J. A., Rastogi A., Anyebuno M. A., Pildes R. S. Early postnatal dexamethasone therapy in premature infants with severe respiratory distress syndrome: a double-blind, controlled study. J Pediatr. 1990 Aug;117(2 Pt 1):273–282. doi: 10.1016/s0022-3476(05)80547-5. [DOI] [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood. Fetal and Neonatal Edition are provided here courtesy of BMJ Publishing Group

RESOURCES